HER2 heterogeneity and treatment response–associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial
Zheqi Li(Sun Yat-sen University), Kornélia Polyák(Dana-Farber Cancer Institute), Laura M. Spring(Massachusetts General Hospital), Denise A. Yardley(Sarah Cannon), Otto Metzger(Dana-Farber Cancer Institute), Ian E. Krop(Yale Cancer Center), Carol Halsey(Oregon Health & Science University), Kami Chiotti(Oregon Health & Science University), Carlos L. Arteaga(The University of Texas Southwestern Medical Center), Paul T. Spellman(Oregon Health & Science University), Marie-Anne Goyette(Dana-Farber Cancer Institute), Patrizia Dell’Orto(University of Milan), Eric P. Winer(University of Vermont), Vandana G. Abramson(Vanderbilt University), Tari A. King(Brigham and Women's Hospital), Giuseppe Viale(University of Milan), Adrienne G. Waks(Harvard University), Avni Kamat(Harvard University Press), Jennifer R. Bellon(Brigham and Women's Hospital), Leila Russo(European Institute of Oncology), Susan C. Lester(University of Vermont)
Cited by 29
Related Papers
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
|Nature reviews. Cancer|2009|3.3k
The Genomic Landscapes of Human Breast and Colorectal Cancers
|Science|2007|2.8k
A model for p53-induced apoptosis
|Nature|1997|2.5k